Regenerative medicine device maker RegenLab USA (RGNA.US) IPO priced at $6-8 per share, plans to raise $18 million.

Zhitong Finance APP has learned that RegenLab USA, a medical device company focused on regenerative medicine applications such as tissue repair, announced the terms of its IPO on Tuesday. The Jersey City, New Jersey-based company plans to offer 2.5 million shares at a price of $6 to $8 per share to raise $18 million. Based on the midpoint of the proposed offering price range, RegenLab USA's fully diluted market capitalization will reach $157 million.